Ocular Therapeut (OCUL)

$12.04 -0.46 (-3.68%)
Market Cap 1.91B
Revenue (ttm) 63.72M
Net Income (ttm) -193.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -303.69%
Debt to Equity Ratio 0.26
Volume 1,275,293
Avg Vol 2,455,190
Day's Range N/A - N/A
Shares Out 159.30M
Stochastic %K 80%
Beta 1.49
Analysts Strong Sell
Price Target $17.75

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Fax: 781 275 7562
Address:
15 Crosby Drive, Bedford, United States
ShortSuckieTuckie
ShortSuckieTuckie Aug. 7 at 1:13 PM
$OCUL $13 today?
1 · Reply
BDE_Worldwide
BDE_Worldwide Aug. 6 at 7:44 PM
$OCUL very interesting day yesterday.. this could be on the verge of breaking out higher.. 🚀
0 · Reply
lilcapman
lilcapman Aug. 6 at 5:25 PM
$OCUL c'mon big O...let's rip through $12.50 (forgive me being a cheerleader...won't happen again until I'm waiting for it to bust $50)
0 · Reply
JarvisFlow
JarvisFlow Aug. 6 at 4:37 PM
Scotiabank has updated their rating for Ocular Therapeutix ( $OCUL ) to Sector Outperform with a price target of 20.
2 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 6 at 4:04 PM
$OCUL Closed out my mad money Aug Calls for 100% profit ($600). I'll watch the October Calls to see if I can get a good buying price next month.
1 · Reply
SmokenTuna
SmokenTuna Aug. 6 at 3:56 PM
$OCUL beast mode!!sept better be a huge event! I say a p2/3 with a monster worldwide partner for DR. We have to go big or go home at this point.
2 · Reply
betonthenews
betonthenews Aug. 6 at 12:39 PM
$OCUL The superiority label is the target in the earnings report, street can have their doubts, but they have to consider the chances OCUL may succeed, IMO.
1 · Reply
JarvisFlow
JarvisFlow Aug. 6 at 10:00 AM
Needham has adjusted their stance on Ocular Therapeutix ( $OCUL ), setting the rating to Buy with a target price of 14 → 15.
0 · Reply
TalkMarkets
TalkMarkets Aug. 6 at 9:04 AM
First Major Red Flag Since April - Bigger Drop Coming? $SPX $FOR $AEM $OCUL https://talkmarkets.com/content/stocks--equities/first-major-red-flag-since-april-bigger-drop-coming?post=513482&userid=166882
0 · Reply
lilcapman
lilcapman Aug. 5 at 8:50 PM
$OCUL https://x.com/zipjet/status/1952718390277079130
1 · Reply
Latest News on OCUL
Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:33 PM EDT - 2 days ago

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Jul 22, 2025, 7:00 AM EDT - 16 days ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 26, 2025, 1:54 PM EDT - 6 weeks ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Jun 16, 2025, 7:00 AM EDT - 7 weeks ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 3 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 11, 2025, 4:30 PM EDT - 4 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 31, 2025, 7:00 AM EDT - 4 months ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Mar 11, 2025, 2:49 PM EDT - 5 months ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Mar 6, 2025, 11:15 AM EST - 5 months ago

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 10:16 AM EST - 5 months ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 24, 2025, 7:00 AM EST - 5 months ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Feb 3, 2025, 7:00 AM EST - 6 months ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Jan 14, 2025, 7:00 AM EST - 7 months ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Is Now Thoroughly Derisked

Dec 30, 2024, 12:16 PM EST - 7 months ago

Ocular Is Now Thoroughly Derisked

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 7:30 AM EST - 8 months ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Dec 2, 2024, 7:30 AM EST - 8 months ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 26, 2024, 7:30 AM EST - 9 months ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:34 AM EST - 9 months ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 13, 2024, 7:30 AM EST - 9 months ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Nov 6, 2024, 7:30 AM EST - 9 months ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 15, 2024, 7:30 AM EDT - 10 months ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

Oct 11, 2024, 5:50 AM EDT - 10 months ago

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

AMD

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Oct 9, 2024, 7:30 AM EDT - 10 months ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 25, 2024, 7:30 AM EDT - 11 months ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:53 PM EDT - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 31, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Jun 20, 2024, 9:13 AM EDT - 1 year ago

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SWKS BFH IRTC TRU

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough

Jun 3, 2024, 2:01 PM EDT - 1 year ago

Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Jun 1, 2024, 5:30 AM EDT - 1 year ago

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 8:16 PM EDT - 1 year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 6, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

May 3, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

May 1, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Apr 6, 2024, 10:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

Mar 26, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

Mar 5, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

ShortSuckieTuckie
ShortSuckieTuckie Aug. 7 at 1:13 PM
$OCUL $13 today?
1 · Reply
BDE_Worldwide
BDE_Worldwide Aug. 6 at 7:44 PM
$OCUL very interesting day yesterday.. this could be on the verge of breaking out higher.. 🚀
0 · Reply
lilcapman
lilcapman Aug. 6 at 5:25 PM
$OCUL c'mon big O...let's rip through $12.50 (forgive me being a cheerleader...won't happen again until I'm waiting for it to bust $50)
0 · Reply
JarvisFlow
JarvisFlow Aug. 6 at 4:37 PM
Scotiabank has updated their rating for Ocular Therapeutix ( $OCUL ) to Sector Outperform with a price target of 20.
2 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 6 at 4:04 PM
$OCUL Closed out my mad money Aug Calls for 100% profit ($600). I'll watch the October Calls to see if I can get a good buying price next month.
1 · Reply
SmokenTuna
SmokenTuna Aug. 6 at 3:56 PM
$OCUL beast mode!!sept better be a huge event! I say a p2/3 with a monster worldwide partner for DR. We have to go big or go home at this point.
2 · Reply
betonthenews
betonthenews Aug. 6 at 12:39 PM
$OCUL The superiority label is the target in the earnings report, street can have their doubts, but they have to consider the chances OCUL may succeed, IMO.
1 · Reply
JarvisFlow
JarvisFlow Aug. 6 at 10:00 AM
Needham has adjusted their stance on Ocular Therapeutix ( $OCUL ), setting the rating to Buy with a target price of 14 → 15.
0 · Reply
TalkMarkets
TalkMarkets Aug. 6 at 9:04 AM
First Major Red Flag Since April - Bigger Drop Coming? $SPX $FOR $AEM $OCUL https://talkmarkets.com/content/stocks--equities/first-major-red-flag-since-april-bigger-drop-coming?post=513482&userid=166882
0 · Reply
lilcapman
lilcapman Aug. 5 at 8:50 PM
$OCUL https://x.com/zipjet/status/1952718390277079130
1 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 5 at 8:04 PM
$OCUL It performed like I hoped it would today. Momentum traders dumped, shorts jumped in and then covered and new/smart buyers bought over the course of the day. I am surprised it recovered all the way to $12+, but very happy!
2 · Reply
Harvo
Harvo Aug. 5 at 7:57 PM
$OCUL I can't see how this sells off on a Dex revenue miss while we are 6 months away from Topline ph3 SOL-1 data. I would rather anticipate reaching close to a 4-5 billion MC by the time that readout comes.
2 · Reply
Tmoney85285
Tmoney85285 Aug. 5 at 6:14 PM
$OCUL let’s play devils advocate- what alarms you about today’s call? Is EYPT going to beat us to the punch? Are you pissed that the ATM was hit despite promises that wouldn’t happen?
3 · Reply
Sneakybeaver898
Sneakybeaver898 Aug. 5 at 5:16 PM
$OCUL this will not trade lower for long! Added more on the dip.
0 · Reply
BigGainTom
BigGainTom Aug. 5 at 4:50 PM
$OCUL This company never shows any sustained increase in revenue. IT should be trading at $5 or less.
1 · Reply
Quantumup
Quantumup Aug. 5 at 3:50 PM
Raymond James reiterated $OCUL Strong Buy-$19, predicated on its constructive view of Axpaxli relative to competing sustained release TKIs and the strategic design of the Axpaxli pivotal program. $REGN $EYPT $APLS $SRZN ALPMY Clear Street reiterated $OCUL Buy-$18 continues to expect strong data from SOL-1, and believe Axpaxli could become standard of care for long duration anti-VEGF injections upon launch as early as 2028. Raymond James and Clear Street said in their notes to investors:
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 5 at 1:56 PM
$OCUL Would love to see this close above $11.50
2 · Reply
lilcapman
lilcapman Aug. 5 at 1:50 PM
$OCUL if you were short or were wanting to initiate or add to a position, today would seem like a pretty decent day to do so
1 · Reply
lilcapman
lilcapman Aug. 5 at 1:45 PM
$OCUL it was an odd call where I thought OCUL made a decison and a change, but there were so many questions and the quick/only response was "we did this for strategic reasons" He said they'll be prepared for 9/30, but the continued questions caused a tad big of a loss of confidence (for the time being) they have a lot of plates spinning, it would seem
0 · Reply
SmokenTuna
SmokenTuna Aug. 5 at 1:42 PM
$OCUL every call same shit. No news and we tank.
4 · Reply
Harvo
Harvo Aug. 5 at 1:23 PM
$OCUL No one is blaming the premarket weirdos for pocessing a high IQ.
1 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 5 at 1:05 PM
$OCUL Still find it odd that there were no questions about NPDR/DME and global market commercialization. It's almost as if the company told analyst not to go there at this point.
1 · Reply